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Sir,
We thank Dr Mesker et al for their comments on our study, (Downey
et al, 2014) recognising their significant work promoting the concept of
using tumour-stroma ratio (TSR) to determine the outcome in cancer
(Mesker et al, 2007, 2009; Courrech Stall et al, 2010, 2011; de Kruijf et al,
2011; Dekker et al, 2013; Huijbers et al, 2013).
None of our ER-positive cohort (118 female, 62 males; Downey et al,
2014) received neoadjuvant therapy of any type. Neoadjuvant treatment
induces pathological changes in the tumour, hence would render samples
unsuitable for TSR analysis. We were limited in the amount of
information that could be supplied in a short communication, however
univariate and multivariate outcomes were provided.
We found high stromal content was related to better survival across
genders in ER-positive disease (Downey et al, 2014), contrasting data in
triple-negative breast cancer (de Kruijf et al, 2011) and, as highlighted by
Mesker et al, their own work on ER-positive cases (de Kruijf et al, 2011;
Dekker et al, 2013). As breast cancer is heterogeneous, subtle differences in
stromal biology may exist between breast cancer subtypes, potentially
impacting on outcome. Notably, tubular carcinoma, a type of invasive
breast ductal carcinoma with an abundant stroma (Figure 1), is almost
always ER-positive and has a favourable prognosis (Rakha et al, 2010).
Methodological heterogeneity exists between sampling methods used to
assess TSR. Two key issues stand out: (1) lack of standardisation in TSR
measurement, (2) area of tissue selected for analysis. Our in-house computer
algorithm method selects a 9 mm2 area of a digitally scanned H&E image
(Downey et al, 2014). Recent related work assessed TSR manually in a single
section from the most invasive tumour area (Gujam et al, 2014). Mesker
et al favour assessment of the whole slide, even suggesting an evaluation of
all available microscope slides. Although rigorous assessment is to be
commended, this technique may have practical implications for histopathol-
ogists should TSR evaluation ever become routine. Alternative approaches
should be considered, compared and validated.
We believe that there is much more to the stroma in dictating outcome,
than simply its proportion in relation to tumour. There is a need to examine
the cell types that coexist within tumour stroma, for example, fibroblasts and
immune cells (Hanahan and Coussens, 2012); a recent issue of this journal
showed that patients with a high TSR had significantly reduced inflammatory
cell infiltrate within their stroma (Gujam et al, 2014). It remains possible that
discrepancies observed between studies of TSR in breast cancer may be due
in part to components of the stromal microenvironment.
Consistent with all emerging techniques it takes time for the ideal
methodology to become accepted in the field. We respectfully suggest the
best way to achieve this for TSR is through collaboration, comparing
different techniques, using carefully selected sub groups of breast cancer
and working towards reaching a consensus, taking account not only of
the stroma but the cells within.
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Figure 1. Tubular carcinoma showing arrangement of tumour cells in
characteristic tubes (stars) embedded within an abundant multicellular
stroma. Scale bar¼ 200mm.
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Sir,
We read this paper by Palmer et al (2014) regarding participation in the
Bowel Cancer Screening Programme (BCSP) with great interest. At the
time of publication we had developed pilot screening education sessions in
South London. By running the programme as a group of health care
professionals (HCPs) consisting of junior doctors, and in partnership with
Bowel Cancer UK, we would assess whether such HCP endorsement
improved screening uptake.
South London area has low screening uptake (unpublished data), and
consists of many communities of socio-economically deprived and ethnic
minority populations. Indeed, previous studies show that such groups
correlate with poor screening uptake (Von Wagner et al, 2011; Lo et al, 2014).
Bowel Cancer UK has links with these community groups, some of whom
invited us to speak, advertising internally to bring our audience. In our pilot
phase, sessions have only been one off, but we anticipate returning annually if
not more frequently, for new participants as well as to maintain bowel cancer
and screening awareness. Education sessions were informal and held at the
convenience of participating groups, via a standardised presentation.
Participants were given information regarding the epidemiology and risk
factors for bowel cancer. In particular, we covered the importance of screening
asymptomatic individuals and performed a demonstration and thorough
explanation of the faecal occult blood (FOB) test. Participants were
encouraged to ask questions before, during and after the presentation, and
were sometimes quizzed during the sessions to enable an educational
experience that was both informative and enjoyable. Feedback using a Likert
scale on how useful the sessions were showed that every participant found the
presentation very useful (85.7%) or quite useful (14.3%).
In our pilot study, we were invited to deliver talks to 43 participants
from three community groups—users of the local library, the local Chinese
association and the local Irish pensioners association. Our talks were
attended disproportionately by women (male: 13; female: 30) due to the
variation in participation in these local community groups. For the same
reason, our sessions were attended by individuals from a wide range of ages
although the majority were aged between 50 and 69 (53.4%). We did not
distinguish between younger (screening naive) and older (screening age)
groups in the hope of positively influencing the decision to participate in
screening when invited in future in the former group, and consolidating the
knowledge and FOB testing know-how in the latter group.
A large proportion of our participants (51%) were of ethnic minority
origin and sometimes interpreters were required for the talks. This is
important as screening uptake in ethnic minorities could be poor
secondary to the language barrier. This draws attention to the potential
influence of discussion to ethnically diverse groups, as Palmer et al held
focus groups comprising mostly white Europeans.
Prior to the education sessions, 63.2% of participants reported
awareness of the screening programme with 41.5% reporting that they
would take part. Their willingness to participate in the screening
programme improved to 85.7% after the talk. Before the session, only
27.9% were aware of the symptoms associated with bowel cancer. This
improved to 92.8% after the talks. Furthermore, 92.8% reported that they
would see their GP if they were to experience any symptoms associated
with bowel cancer. Moreover, 82.1% felt more comfortable talking about
bowel cancer and the screening programme with friends and family. This
increased willingness to participate in the screening programme after the
educational programme draws parallels to the findings by Palmer et al,
after their participants had the opportunity to discuss screening with
others. However, despite the improvement in the understanding of bowel
cancer and risk factors, only 23–50% expressed willingness to make
lifestyle changes such as smoking cessation. Annual sessions would serve
as follow-up to assess whether participants actually took part in
screening after an educational session.
Although our pilot study looked at a very small number of
participants, our results have been consistent with the qualitative data
collected by Palmer et al in showing the benefits of discussion to dispel
misconceptions and also to encourage and support participation in the
screening programme. Palmer et al reported that many participants
claimed they were more likely to participate in FOB testing if it were
endorsed by HCPs. Further research with larger groups of people may
prove to be beneficial in assessing whether running wide-scale HCP-
endorsed bowel cancer screening is cost-effective to bring long-term
improvement to the uptake of bowel cancer screening.
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